<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02192697</url>
  </required_header>
  <id_info>
    <org_study_id>8273-CL-0101</org_study_id>
    <nct_id>NCT02192697</nct_id>
  </id_info>
  <brief_title>An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations</brief_title>
  <official_title>Phase I and II Study of ASP8273 — An Open-label Study of the Oral Administration of ASP8273 in Patients With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Mutations —</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to determine the following in patients with non-small cell lung
      cancer (NSCLC) harboring EGFR activating mutations.

        -  the safety and tolerability of ASP8273.

        -  the pharmacokinetics (PK) of ASP8273.

        -  the antitumor activity of ASP8273.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of Phase I and Phase II.

      The objectives of Phase I are to determine the following in patients with non-small cell lung
      cancer (NSCLC) harboring EGFR activating mutations.

        -  safety and tolerability of ASP8273.

        -  the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of ASP8273
           based on the dose limiting toxicity (DLT) profile.

        -  pharmacokinetics (PK) of ASP8273.

        -  antitumor activity of ASP8273.

      The objectives of Phase II are to determine the following at the RP2D of ASP8273 in patients
      with NSCLC harboring EGFR mutation.

        -  efficacy of ASP8273

        -  safety of ASP8273

        -  PK of ASP8273
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.
  </why_stopped>
  <start_date type="Actual">January 23, 2014</start_date>
  <completion_date type="Actual">June 22, 2017</completion_date>
  <primary_completion_date type="Actual">January 15, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Safety and tolerability of ASP8273 as assessed by Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to Day 23</time_frame>
    <description>A DLT is defined as any pre-determined toxicity that is related to study drug per the investigator and which occurs during Cycle 0 and Cycle 1 using the Japan Clinical Oncology Group (JCOG) Japanese translation of the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE ver 4.0 - JCOG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Overall response rate (CR+PR) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The overall response rate, which is defined as the proportion of subjects whose best overall response is rated as complete response (CR) or partial response (PR) according to RECIST Version 1.1, will be calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Safety and tolerability of ASP8273 as assessed by adverse events (AEs)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a subject administered a study drug or has undergone study procedures and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Safety and tolerability of ASP8273 as assessed by laboratory tests</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Laboratory tests to be conducted are hematology, biochemistry, urinalysis, coagulation profile, lipid panel and lymphocyte subpopulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Safety and tolerability of ASP8273 as assessed by vital signs</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Vital signs to be measured includes blood pressure, pulse rate and temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Safety and tolerability of ASP8273 as assessed by 12-lead ECG</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>including the assessment of QT intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Plasma concentrations of unchanged ASP8273</measure>
    <time_frame>Up to Day 1 of Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Urine concentrations of unchanged ASP8273</measure>
    <time_frame>Up to Day 1 of Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Overall response rate (CR+PR)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The overall response rate is defined as the proportion of subjects whose best overall response is rated as complete response (CR) or partial response (PR) according to RECIST Version 1.1, will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Disease control rate (CR+PR+SD)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The disease control rate is defined as the proportion of subjects whose best overall response is rated as CR, PR, or stable disease (SD) according to RECIST Version 1.1, will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Plasma concentrations of unchanged ASP8273</measure>
    <time_frame>Up to Day 1 of Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Urine concentrations of unchanged ASP8273</measure>
    <time_frame>Up to Day 1 of Cycle 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Safety and tolerability of ASP8273 as assessed by adverse events (AEs)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a subject administered a study drug or has undergone study procedures and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Safety and tolerability of ASP8273 as assessed by laboratory tests</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Laboratory tests to be conducted are hematology, biochemistry, urinalysis, coagulation profile, lipid panel and lymphocyte subpopulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Safety and tolerability of ASP8273 as assessed by vital signs</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Vital signs to be measured includes blood pressure, pulse rate and temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Safety and tolerability of ASP8273 as assessed by 12-lead ECG</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>including the assessment of QT intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Disease control rate</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The disease control rate is defined as the proportion of subjects whose best overall response is rated as CR, PR, or stable disease (SD) according to RECIST Version 1.1, will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Progression-free survival (PFS)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall survival (OS)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall response rate (CR+PR)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The overall response rate, which is defined as the proportion of subjects whose best overall response is rated as complete response (CR) or partial response (PR) according to RECIST Version 1.1, will be calculated</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I dose-escalation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I EGFR-T790M mutation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP8273</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Phase II group</arm_group_label>
    <arm_group_label>Phase I dose-escalation group</arm_group_label>
    <arm_group_label>Phase I EGFR-T790M mutation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of NSCLC.

          -  Patients confirmed to have the del ex19, L858R, G719X, or L861Q mutation among the
             EGFR activating mutations (patients at the study site who are documented to have any
             of the above-stated EGFR activating mutations can be enrolled in the study).

          -  Life expectancy ≥ 12 weeks based on the investigator's/subinvestigator's judgment.

          -  [Phase I]

               -  Patients who have previously been treated with EGFR tyrosine-kinase inhibitors
                  (EGFR-TKIs)*

               -  Those who are not expected to show a therapeutic response to existing treatments
                  in the investigator's/subinvestigator's opinion.

          -  [Phase II]

               -  Patients who have been confirmed to have progressive disease (PD) after previous
                  treatment with EGFR-TKIs*; for those who have received 2 or more regimens of
                  previous treatment, the last regimen before enrollment should have included
                  EGFR-TKIs.

               -  *Erlotinib, gefitinib, and EGFR-TKIs under clinical investigation (e.g.,
                  neratinib, afatinib, dacomitinib)

               -  Expression of the EGFR-T790M mutation as confirmed by a tumor biopsy of the
                  primary or metastatic lesions after confirmation of PD following previous
                  treatment with EGFR-TKIs and before enrollment, or by a tumor tissue sample that
                  had been collected and archived after confirmation of PD following previous
                  treatment with EGFR-TKIs.

               -  At least 1 measurable lesion based on Response Evaluation Criteria in Solid
                  Tumors (RECIST) Version 1.1.

        Exclusion Criteria:

          -  Persistent clinical evidence of previous antitumor treatment related toxicity ≥ Grade
             2 using the Japan Clinical Oncology Group (JCOG) Japanese translation of the National
             Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version
             4.0 (NCI CTCAE v4.0 - JCOG) (except alopecia and skin toxicities considered irrelevant
             in study enrollment by the investigator/sub-investigator).

          -  History of or concurrent interstitial lung disease

          -  Received treatment with a reversible EGFR-TKI (erlotinib or gefitinib) within 8 days
             before the start of the study treatment.

          -  Received previous treatment (except reversible EGFR-TKIs) intended to have antitumor
             effects or treatment with another investigational drug or an investigational device
             within 14 days before the start of the study treatment.

          -  Previously received treatment with EGFR-TKIs (e.g., CO-1686, AZD9291) that can inhibit
             EGFR with the T790M mutation.

          -  It is planned that the subject will undergo a surgical procedure during the course of
             the study or the subject still has an unhealed wound after previous surgery

          -  Symptomatic central nervous system (CNS) lesions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: 4</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 9</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 8</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 7</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 6</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 2</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 1</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 10</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 11</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 12</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 13</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 14</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>July 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2014</study_first_posted>
  <last_update_submitted>July 9, 2017</last_update_submitted>
  <last_update_submitted_qc>July 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>tolerability</keyword>
  <keyword>ASP8273</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>T790M resistance mutation</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Epidermal Growth Factor Receptor mutations</keyword>
  <keyword>irreversible EGFR inhibitor</keyword>
  <keyword>antitumor activity</keyword>
  <keyword>EGFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

